Provided by Tiger Trade Technology Pte. Ltd.

Biomea Fusion, Inc.

1.30
-0.0300-2.26%
Post-market: 1.340.0400+3.08%19:30 EDT
Volume:1.07M
Turnover:1.41M
Market Cap:93.99M
PE:-2.76
High:1.36
Open:1.32
Low:1.30
Close:1.33
52wk High:2.99
52wk Low:0.8719
Shares:72.30M
Float Shares:67.01M
Volume Ratio:0.55
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4711
EPS(LYR):-1.1832
ROE:-164.14%
ROA:-63.46%
PB:7.74
PE(LYR):-1.10

Loading ...

Biomea Fusion price target lowered to $7 from $9 at Citizens

TIPRANKS
·
Aug 07

Biomea Fusion (BMEA) Gets a Buy from Oppenheimer

TIPRANKS
·
Aug 06

PepGen Q2 Net Loss Narrows as Expenses Fall

Reuters
·
Aug 06

Amylyx Pharmaceuticals Q2 Posts Higher than Expected Loss

Reuters
·
Aug 06

Analyst Maintains Buy Rating on Biomea Fusion as Metabolic Pipeline Advances and $4 Price Target Remains Unchanged

TIPRANKS
·
Aug 06

Biomea Fusion, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Biomea Fusion Q2 EPS $(0.12) Beats $(0.22) Estimate

Benzinga Earnings
·
Aug 06

Biomea Fusion reports Q2 EPS (12c), consensus (23c)

TIPRANKS
·
Aug 06

Biomea Fusion Q2 Loss Narrows, Cash Runway into Q2 2027

Reuters
·
Aug 06

Biomea Fusion Q2 Net Loss Narrows to $8.33 Million; R&D Expenses Fall 44.68% to $9.14 Million

Reuters
·
Aug 06

Biomea Fusion Q2 Basic EPS USD -0.12

THOMSON REUTERS
·
Aug 06

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

GlobeNewswire
·
Aug 06

Biomea Fusion Inc Expected to Post a Loss of 22 Cents a Share - Earnings Preview

Reuters
·
Aug 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Jul 31

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)

TIPRANKS
·
Jun 24

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Novavax (NVAX)

TIPRANKS
·
Jun 12

Biomea Fusion shareholders elect two directors at annual meeting

Reuters
·
Jun 11

Biomea Labs: Buy Rating Reiterated as Icovamenib Data Strengthen Metabolic Disease Thesis; $4 Price Target Maintained

TIPRANKS
·
Jun 08

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“Ada”) 86TH Scientific Sessions and Announces Expansion of Ongoing Phase I Bmf-650 Study

THOMSON REUTERS
·
Jun 06

Biomea Fusion - Icovamenib Data Show Muscle Preservation and Fat Reduction in Obesity and Diabetes

THOMSON REUTERS
·
Jun 06